Specifications - Aventis Recombinant Insulin Plant, Frankfurt, Germany

Key Data
Order year	April 2001
Project type	New Plant
Location	Frankfurt, Germany
Estimated investment	€150 million
Completion	Mid-2003
Key Players
Sponsor	Aventis Pharma Germany, Pfizer, Diabel
Lead engineer / designer	Linde-KCA-Dresden
Validation	Linde-KCA-Dresden
Financing	Aventis Pharma Germany, Pfizer
Output Chemicals
Type	Human recombinant insulin
Featured Suppliers
Senn Chemicals - Amino Acid Derivatives, Un-Natural Amino Acids, Peptides, Resins, Carbohydrates And Reagents For The Pharmaceutical, Nutraceutical + Cosmetic Industry
Whitehouse Scientific - High Precision Glass Microspheres for Calibration Purposes